Alternative pathways involving MYC and its targets could help distinguish between two types of morphologically similar lymphomas, such as tFL-derived DLBCL and de novo DLBCL, this signature being more enriched in de novo cases than in transformed ones [172]. The gene discussed is MYC; the disease is lymphoma.